The plant-based biologics market comprises pharmaceuticals produced through plant cell culture or transient plant expression systems. Plant-based biologics offer cost-effective production and are considered more environmentally-friendly and morally acceptable compared to conventional sources. This has boosted research to develop plant-based versions of vaccines, antibodies and other biologics.
The global plant-based biologics market is estimated to be valued at US$ 17.7 Mn in 2023 and is expected to exhibit a CAGR of 3.4% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growing demand for affordable healthcare has propelled the plant-based biologics market. Production of biologics through conventional microbial fermentation or cell culture methods are capital intensive and resource intensive, making the end products expensive. In contrast, plant-based production systems offer 20-30% lower costs and higher productivity compared to microbial systems. Plant cells offer human-like post-translational modifications and require simpler downstream processing compared to microbial and animal cell cultures. This has enhanced research on plant-made pharmaceuticals, which are more affordable and can improve access to life-saving biologics in developing regions.
SWOT Analysis
Strength: Plant-based biologics have a lower risk of viral contamination and lower production costs compared to conventional biologics produced in mammalian cell cultures. They can be genetically modified easier to provide enhanced functionality.
Weakness: Lack of technologies and regulatory framework for commercial production and clinical trials. Complex nature of plants make product purification and standardization challenging. Higher immunogenicity risk compared to mammalian cell culture systems.
Opportunity: Growing demand for safe, affordable, and sustainable alternatives to conventional biologics for various therapeutic areas like oncology and vaccines. Increasing focus on precision medicine and personalized therapies also offer opportunities.
Threats: Established mammalian systems have significant technological advantages over plant-based systems currently. Regulatory pathways need to be established which can delay market entry. Intellectual property issues around gene libraries and expression technologies.
Key Takeaways
The global plant-based biologics market is expected to witness high growth over the forecast period driven by advantages over conventional biomanufacturing and growing biologics demand.
Regional analysis: North America dominates currently due to presence of key research institutes and companies in US and Canada. Europe and Asia Pacific also offer growth opportunities led by countries like UK, Germany, China and India supporting development through funding and pilot plants.
Key players operating in the plant-based biologics market are Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis B.V. Manufacturers are focusing on partnerships for technology access and clinical validation to gain market share.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
About Author – Priya Pandey
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor’s degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya’s meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. LinkedIn Profile